Temixys FDA Approval History
FDA Approved: Yes (First approved November 16, 2018)
Brand name: Temixys
Generic name: lamivudine and tenofovir disoproxil fumarate
Dosage form: Tablets
Company: Celltrion USA
Treatment for: HIV Infection
Temixys (lamivudine and tenofovir disoproxil fumarate) is a combination of two nucleoside reverse transcriptase inhibitors indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
